ÂÜÀòÂÒÂ×

Matt Hellmann currently serves as Vice President of Early Oncology Development within the Oncology R&D division at AstraZeneca, where responsibilities include overseeing a global team of over 500 professionals and leading a diverse portfolio of approximately 25 early-stage oncology medicines, with a focus on solid tumors. Previously, as Vice President of Early Oncology Clinical, Hellmann managed a team of approximately 200 experts in planning and executing early clinical trials. Prior experience includes serving as an Attending Physician at Memorial Sloan Kettering Cancer Center. Matt Hellmann's education includes a medical degree from Johns Hopkins University School of Medicine, a residency at Massachusetts General Hospital, and a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center.